News
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research raises price target for Pharming Group NV after Q3/24 results. CEO not seeking reappointment unrelated to business. Market undervaluing APDS drug sales potential. Expect significant revenue growth -
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
-
COMMUNIQUÉ DE PRESSE
Original-Research: Pharming (von First Berlin Equity Research GmbH): Buy